Effect of DNA damage of cumulus oophorus cells and lymphocytes analyzed by alkaline comet assay on oocyte quality and intracytoplasmic sperm injection success among patients with polycystic ovary syndrome

2018 ◽  
Vol 45 (3) ◽  
pp. 609-618
Author(s):  
Esra N. Tola ◽  
Pınar A. Koşar ◽  
Dilek U. Karatopuk ◽  
Okan Sancer ◽  
Baha Oral
Keyword(s):  
Dna Damage ◽  
Polycystic Ovary Syndrome ◽  
Comet Assay ◽  
Intracytoplasmic Sperm Injection ◽  
Polycystic Ovary ◽  
Oocyte Quality ◽  
Alkaline Comet Assay ◽  
Ovary Syndrome ◽  
Cumulus Oophorus

A Meta-Analysis of Oocyte Quality and Clinical Outcome of Intracytoplasmic Sperm Injection Cycles in Patients with Polycystic Ovary Syndrome

2018 ◽  
Vol 8 (9) ◽  
pp. 1886-1894
Author(s):  
Na Duan ◽  
Hui Wang ◽  
Ziru Niu ◽  
Yifan Guo ◽  
Shuling Wang ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Intracytoplasmic Sperm Injection ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Statistical Significance ◽  
Oocyte Quality ◽  
Cochrane Library ◽  
Miscarriage Rate ◽  
Ovary Syndrome ◽  
Pcos Group

Whether treatment outcomes in intracytoplasmic sperm injection (ICSI) cycles differ between polycystic ovary syndrome (PCOS) and non-PCOS patients remains inconclusive. The aim of this meta-analysis is to compare oocyte quality and clinical outcomes in PCOS patients and non-PCOS patients undergoing ICSI procedure. Methods: Databases including Medline, Embase and the Cochrane Library were searched for studies published up to 18 January 2018. All articles searched were independently reviewed and selected by two evaluators according to predetermined inclusion and exclusion criteria. Results: Eight studies were selected for inclusion, and a total of 474 PCOS patients (627 cycles) were compared to age-matched controls (962 patients, 992 cycles). The total gonadotropin usage was significant less in PCOS group, and the MD was –481.72 IU [95% CI:– 603.76–359.68, P < 0.00001]. A significantly higher mean number of oocytes, metaphase II (MII) oocytes and 2-pronucleated (2PN) oocytes per cycle were observed in the PCOS group than in the non-PCOS group (P < 0.005), the total MDs were 4.20 [95% CI: 2.50–5.90], 1.52 [95% CI: 0.84–2.20] and 1.71 [95% CI: 0.73–2.69], respectively. The fertilization rate was comparable. The clinical pregnancy rate per transfer cycle was higher in the PCOS group, the odd ratio (OR) was 1.59 [95% CI: 1.23–2.05, P < 0.005] and the live birth rate was comparable. A higher miscarriage rate was observed in the PCOS group, but this did not reach statistical significance. The risk of ovarian hyperstimulation syndrome (OHSS) was significantly higher in the PCOS group [OR: 3.01, 95% CI: 1.16–7.82, P < 0.05]. Conclusions: This meta-analysis demonstrated that PCOS patients may have more favourable ICSI outcomes than non-PCOS patients. Our findings should be evaluated in further prospective cohort studies.

scholarly journals Evaluation of DNA damage profile in obese women and its association to risk of metabolic syndrome, polycystic ovary syndrome and recurrent preeclampsia

2018 ◽  
Vol 5 (4) ◽  
pp. 367-373 ◽  
Author(s):  
Moushira Zaki ◽  
Walaa Basha ◽  
Hala T. El-Bassyouni ◽  
Safinaz El-Toukhy ◽  
Tamer Hussein
Keyword(s):  
Metabolic Syndrome ◽  
Dna Damage ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Obese Women ◽  
Ovary Syndrome

N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin

2016 ◽  
Vol 28 (6) ◽  
pp. 723 ◽  
Author(s):  
Ebrahim Cheraghi ◽  
Malek Soleimani Mehranjani ◽  
Mohammad Ali Shariatzadeh ◽  
Mohammad Hossein Nasr Esfahani ◽  
Zahra Ebrahimi
Keyword(s):  
Placebo Group ◽  
Polycystic Ovary Syndrome ◽  
Intracytoplasmic Sperm Injection ◽  
Embryo Quality ◽  
Polycystic Ovary ◽  
Treated Group ◽  
Ovary Syndrome ◽  
Total Data ◽  
Oocyte Aspiration ◽  
Fluid Parameters

Polycystic ovary syndrome (PCOS) is associated with low-quality oocytes. The aim of the present study was to investigate the effects of metformin (MET), N-acetylcysteine (NAC) and their combination on follicular fluid parameters, oocytes and embryo quality in PCOS patients. A prospective randomised placebo-controlled pilot study on 60 Iranian women with PCOS (aged 25–35 years) undergoing intracytoplasmic sperm injection (ICSI) was designed. Women were divided into four groups (n = 15 in each): (1) an MET, administered 1500 mg day–1 MET; (2) an NAC group, administered 1800 mg day–1 NAC; (3) an NAC + MET group; and (4) a placebo group. Drugs were administered from the 3rd day of previous cycle until the day of oocyte aspiration (6 weeks treatment in total). Data were analysed by one-way ANOVA, with significance set at P < 0.05. The number of immature and abnormal oocytes decreased significantly in the NAC compared with placebo group, with a concomitant increase in the number of good-quality embryos in the NAC group (P < 0.05). Malondialdehyde levels decreased significantly in the NAC and NAC + MET groups compared with the placebo-treated group (P < 0.02). In addition, there were significant decreases in leptin levels in the NAC, MET and NAC + MET groups compared with the placebo group (P < 0.001). Insulin and LH levels were significantly lower in the MET and NAC groups compared with the placebo-treated group (P < 0.02). We concluded that NAC improves oocyte and embryo quality and could be administered as an alternative to MET.

Sign in / Sign up

Export Citation Format

Share Document